SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease.

Wang, Pengfei, Liu, Lihong, Nair, Manoj S, Yin, Michael T, Luo, Yang, Wang, Qian, Yuan, Ting, Mori, Kanako, Solis, Axel Guzman, Yamashita, Masahiro, Garg, Ankur, Purpura, Lawrence J, Laracy, Justin C, Yu, Jian, Joshua-Tor, Leemor, Sodroski, Joseph, Huang, Yaoxing, Ho, David D (December 2020) SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. Emerging Microbes and Infections, 9 (1). pp. 2091-2093. ISSN 2222-1751

[img] PDF
2020.Wang.NeutralizingAntibodiesCovid19.pdf - Published Version

Download (1MB)
URL: https://www.ncbi.nlm.nih.gov/pubmed/32930052
DOI: 10.1080/22221751.2020.1823890

Abstract

We studied plasma antibody responses of 35 patients about 1 month after SARS-CoV-2 infection. Titers of antibodies binding to the viral nucleocapsid and spike proteins were significantly higher in patients with severe disease. Likewise, mean antibody neutralization titers against SARS-CoV-2 pseudovirus and live virus were higher in the sicker patients, by ∼5-fold and ∼7-fold, respectively. These findings have important implications for those pursuing plasma therapy, isolation of neutralizing monoclonal antibodies, and determinants of immunity.

Item Type: Paper
Subjects: diseases & disorders > viral diseases > coronavirus > covid 19
organs, tissues, organelles, cell types and functions > cell types and functions > cell functions > immunity
CSHL Authors:
Communities: CSHL labs > Joshua-Tor lab
SWORD Depositor: CSHL Elements
Depositing User: CSHL Elements
Date: December 2020
Date Deposited: 06 May 2021 15:15
Last Modified: 06 May 2021 15:15
PMCID: PMC7534308
URI: https://repository.cshl.edu/id/eprint/40003

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving